|Articles|June 9, 2004
Santen Pharmaceuticals ends phaco device development
Phacor Inc., the California-based wholly owned subsidiary of Santen Pharmaceuticals Co. Ltd., ceased operations after 6 years of phacoemulsification system development.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
























